Insider trade

Krystal Biotech (KRYS): Chief Accounting Officer sold ~$1.55M

Kathryn Romano, Chief Accounting Officer at Krystal Biotech, sold ~$1.55M of Krystal Biotech shares.

~$1.55M
Approx. value · 5,700 sh @ $271.66
24K
Holds after · shares reported
Traded
Feb 9, 2026
Filed
Feb 12, 2026

What stands out in this filing

  • The sale was 19.1% of the shares this insider held before it; the filing reports 24,118 shares afterwards.
  • 5,700 shares at an average of $271.66 each, as reported on the form.
  • Filing box checked: sold under a Rule 10b5-1 plan.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

The company's last weighty Form 8-K report up to this date: reported its results, 29 days earlier (Jan 11, 2026). The first one after it: reported its results, 8 days later (Feb 17, 2026).

  1. Company filing · Form 8-K · Executive changeChanged a top executive or board member“On December 22, 2025, Kirti Ganorkar gave notice of his resignation from the Board of Directors (the “Board”) of Krystal Biotech, Inc. (the “Company”).”
  2. Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
  3. InsiderOfficer sold ~$1.55M of KRYS shares in the open market

What came next

  1. Insider · 1 personInsiders: 6 sales (~$1.9M)
  2. Company filing · Form 8-K · ResultsReported its results
  3. Insider · 1 personInsiders: 2 sales (~$5.0M)
  4. Insider · 1 personInsiders: 17 sales (~$13.8M)
  5. InsiderDirector sold ~$193K of KRYS shares in the open market
  6. Insider · 1 personInsiders: 2 sales (~$2.1M)
  7. Insider · 1 personInsiders: 2 sales (~$3.3M)
  8. InsiderOfficer sold ~$201K of KRYS shares in the open market
  9. Insider · 2 peopleInsiders: 20 sales (~$13.2M)
  10. InsiderOfficer sold ~$194K of KRYS shares in the open market
  11. Insider · 2 peopleInsiders: 22 sales (~$15.4M)
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Krystal Biotech

For Krystal Biotech, OQRO holds 26 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its KRYS page.

Other recent filings by Kathryn Romano, Chief Accounting Officer

The full history of Kathryn Romano, Chief Accounting Officer is on the profile page.

How this filing works

Explore the data

Common questions

Which Krystal Biotech (KRYS) insider traded, and how much?

Kathryn Romano, Chief Accounting Officer at Krystal Biotech, sold ~$1.55M of Krystal Biotech shares. 5,700 shares at $271.66.

When did it happen, and when was it made public?

Traded: Feb 9, 2026. Filed: Feb 12, 2026. That is 3 days between the two dates.

What stands out in this filing?

The sale was 19.1% of the shares this insider held before it; the filing reports 24,118 shares afterwards. 5,700 shares at an average of $271.66 each, as reported on the form. Filing box checked: sold under a Rule 10b5-1 plan.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Krystal Biotech recently?

For Krystal Biotech, OQRO holds 26 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the KRYS page.

Does this mean KRYS stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Krystal Biotech

Everything OQRO holds on this company is on its KRYS page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data